Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome
| Autor: | Palandri, Francesca, Iacobucci, Ilaria, Castagnetti, Fausto, Testoni, Nicoletta, Poerio, Angela, Amabile, Marilina, Breccia, Massimo, Intermesoli, Tamara, Iuliano, Francesco, Rege Cambrin, Giovanna, Tiribelli, Mario, Miglino, Maurizio, Pane, Fabrizio, Saglio, Giuseppe, Martinelli, Giovanni, Rosti, Gianantonio, Baccarani, Michele, GIMEMA CML Working Party, Bocchia, Monica |
|---|---|
| Přispěvatelé: | Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, GIMEMA Working Party on CML., Francesca, Palandri, Ilaria, Iacobucci, Fausto, Castagnetti, Nicoletta, Testoni, Angela, Poerio, Marilina, Amabile, Massimo, Breccia, Tamara, Intermesoli, Francesco, Iuliano, Giovanna Rege, Cambrin, Mario, Tiribelli, Maurizio, Miglino, Pane, Fabrizio, Giuseppe, Saglio, Giovanni, Martinelli, Gianantonio, Rosti, Michele, Baccarani, G. I., M. |
| Rok vydání: | 2008 |
| Předmět: |
Oncology
medicine.medical_specialty Time Factors Phases of clinical research Alpha interferon IMATINIB Disease-Free Survival Piperazines Cohort Studies Chronic myeloid leukemia Imatinib Interferon-alpha Long-term results Antineoplastic Combined Chemotherapy Protocols Benzamides Cytogenetics Follow-Up Studies Humans Imatinib Mesylate Immunologic Factors Leukemia Myelogenous Chronic BCR-ABL Positive Patient Compliance Pyrimidines Treatment Outcome Hematology Pegylated interferon Internal medicine medicine Chronic Interferon alfa CHRONIC MYELOID LEUKEMIA Leukemia business.industry Myeloid leukemia medicine.disease Imatinib mesylate Immunology BCR-ABL Positive business Myelogenous medicine.drug Chronic myelogenous leukemia |
| Zdroj: | Haematologica. 93:770-774 |
| ISSN: | 1592-8721 0390-6078 |
| DOI: | 10.3324/haematol.12265 |
| Popis: | In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-alpha in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-alpha. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|